Investing News NetworkYour trusted source for investing success
Helium Evolution
Integrated Cyber Solutions
Purepoint Uranium
Argentina Lithium & Energy
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Pharmadrug
Developing Pharma-Grade Medical Cannabis in Europe
Overview
Pharmadrug Inc. (CSE:BUZZ,OTC:LMLLF) is a German medical cannabis distributor with an 80 percent ownership in Pharmadrug Production GmbH, a Schedule I European Union narcotics license holder with the ability to import and distribute medical cannabis in Germany and throughout the EU. In addition, the company owns a convertible note into 54 percent equity of HolyCanna Ltd., a cultivation and nursery license holder in Israel, and has a binding LOI to purchase 57 percent of CannabiSendak Ltd., the builder of a network of dispensaries in Israel.
Pharmadrug Company Highlights
- Pharmadrug is a pure-play on the European cannabis market, which is expected to be the biggest consumer of cannabis in the world with more than 740 million people.
- The company owns 80 percent of Pharmadrug, one of 15 holders of a Class I narcotics license to import and distribute medical cannabis in Germany and anywhere in EU.
- Strategic investments in Israel from seed-to-sale.
- Upside in the high margin, downstream extraction space.
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.Â